Healthequity (NASDAQ:HQY) issued an update on its FY20 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $1.23-1.29 for the period, compared to the Thomson Reuters consensus estimate of $1.31. The company issued revenue guidance of $333-339 million, compared to the consensus revenue estimate of $336.89 million.Healthequity also updated its FY 2020 guidance to $1.23-1.29 EPS.
Shares of HQY opened at $84.51 on Wednesday. The firm has a market capitalization of $5.17 billion, a price-to-earnings ratio of 88.96, a PEG ratio of 2.78 and a beta of 1.72. Healthequity has a 52 week low of $50.29 and a 52 week high of $101.58.
Healthequity (NASDAQ:HQY) last announced its quarterly earnings data on Monday, March 18th. The company reported $0.21 EPS for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.06. The firm had revenue of $75.78 million for the quarter, compared to analyst estimates of $74.28 million. Healthequity had a return on equity of 13.97% and a net margin of 25.73%. The business’s quarterly revenue was up 25.4% compared to the same quarter last year. During the same period last year, the company earned $0.09 EPS. On average, equities research analysts predict that Healthequity will post 1.03 earnings per share for the current fiscal year.
A number of research analysts have commented on HQY shares. Zacks Investment Research upgraded Healthequity from a hold rating to a buy rating and set a $83.00 price objective on the stock in a research report on Monday, December 10th. ValuEngine lowered Healthequity from a strong-buy rating to a buy rating in a research report on Wednesday, December 5th. BidaskClub raised Healthequity from a hold rating to a buy rating in a research note on Saturday, December 1st. Citigroup set a $102.00 price target on Healthequity and gave the company a buy rating in a research note on Tuesday, January 8th. Finally, SunTrust Banks raised Healthequity from a hold rating to a buy rating and set a $81.00 price target on the stock in a research note on Thursday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $86.85.
In other news, EVP Delano Ladd sold 6,875 shares of the stock in a transaction on Wednesday, February 20th. The stock was sold at an average price of $78.00, for a total value of $536,250.00. Following the transaction, the executive vice president now owns 14,340 shares of the company’s stock, valued at approximately $1,118,520. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Darcy G. Mott sold 4,000 shares of the firm’s stock in a transaction on Tuesday, January 22nd. The stock was sold at an average price of $60.81, for a total value of $243,240.00. Following the sale, the vice president now directly owns 79,200 shares in the company, valued at approximately $4,816,152. The disclosure for this sale can be found here. In the last three months, insiders sold 18,875 shares of company stock worth $1,332,090. 4.00% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Healthequity (HQY) Releases FY20 Earnings Guidance” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2019/03/20/healthequity-hqy-releases-fy20-earnings-guidance.html.
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
See Also: How does a 12b-1 fee affect fund performance?
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.